{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:31:18Z","timestamp":1783096278945,"version":"3.54.6"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ60429"],"award-info":[{"award-number":["2023JJ60429"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ30863"],"award-info":[{"award-number":["2022JJ30863"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital, Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.116060","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T17:21:12Z","timestamp":1765992072000},"page":"116060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["First-line therapies analysis in advanced\/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq"],"prefix":"10.1016","volume":"169","author":[{"given":"Yupeng","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenzi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.116060_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","article-title":"Progress in systemic therapy for advanced-stage urothelial carcinoma","volume":"21","author":"Nadal","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103683","article-title":"Recent therapeutic advances in urothelial carcinoma: a paradigm shift in disease management","volume":"174","author":"Bellmunt","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.intimp.2025.116060_bb0015","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/13696998.2020.1770261","article-title":"The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States","volume":"23","author":"Slater","year":"2020","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.intimp.2025.116060_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-019-0609-6","article-title":"Treatment approaches for cisplatin-ineligible patients with invasive bladder Cancer","volume":"20","author":"Einstein","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","article-title":"Management of metastatic bladder cancer","volume":"76","author":"Nadal","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2025.116060_bb0030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2025.116060_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102187","article-title":"Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: applying clinical trial findings to clinical practice","volume":"97","author":"Grivas","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2025.116060_bb0040","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"New England J. Med."},{"key":"10.1016\/j.intimp.2025.116060_bb0045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupret","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.intimp.2025.116060_bb0055","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","article-title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","volume":"25","author":"Grande","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0065","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.116060_bb0070","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2025.116060_bb0075","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.116060_bb0080","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of Sacituzumab Govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, Multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.116060_bb0090","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and pembrolizumab in untreated advanced urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.116060_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin plus pembrolizumab in previously untreated advanced urothelial Cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0100","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.intimp.2025.116060_bb0105","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of Disitamab Vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0110","doi-asserted-by":"crossref","first-page":"21159","DOI":"10.1002\/cam4.6680","article-title":"Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: a multicenter, retrospective clinical study","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2025.116060_bb0115","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1093\/oncolo\/oyad070","article-title":"HER2 expression associated with clinical characteristics and prognosis of urothelial carcinoma in a Chinese population","volume":"28","author":"Zhou","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2025.116060_bb0120","first-page":"1084","article-title":"Identification of a novel prognostic signature based on vitamin metabolism clustering-related genes in lung adenocarcinoma. Transl lung","volume":"13","author":"Chen","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.116060_bb0125","first-page":"1277","article-title":"Bioinformatics analysis of an immunotherapy responsiveness-related gene signature in predicting lung adenocarcinoma prognosis. Transl lung","volume":"13","author":"Jiang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.116060_bb0130","article-title":"Prognosis and immunotherapy response with a novel Golgi apparatus signature-based formula in lung adenocarcinoma","volume":"9","author":"Jiang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2025.116060_bb0135","article-title":"A prognostic risk score based on hypoxia-, immunity-, and Epithelialto-mesenchymal transition-related genes for the prognosis and immunotherapy response of lung adenocarcinoma","volume":"9","author":"Ouyang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2025.116060_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217159","article-title":"RNA ac(4)C modification in cancer: Unraveling multifaceted roles and promising therapeutic horizons","volume":"601","author":"Ouyang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2025.116060_bb0145","article-title":"AI-based multimodal multi-tasks analysis reveals tumor molecular heterogeneity, predicts preoperative lymph node metastasis and prognosis in papillary thyroid carcinoma: a retrospective study","author":"Yu","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.intimp.2025.116060_bb0150","first-page":"7818","article-title":"Unraveling the unfolded protein response signature: implications for tumor immune microenvironment heterogeneity and clinical prognosis in stomach cancer","volume":"16","author":"Ouyang","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.intimp.2025.116060_bb0155","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0160","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur. Urol."},{"key":"10.1016\/j.intimp.2025.116060_bb0165","doi-asserted-by":"crossref","first-page":"14325","DOI":"10.1096\/fj.201901468RR","article-title":"Fluorofenidone protects against acute kidney injury","volume":"33","author":"Jiang","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2025.116060_bb0170","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/0113894501294182240401060343","article-title":"Cisplatin-based combination therapy for enhanced Cancer treatment","volume":"25","author":"Li","year":"2024","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.intimp.2025.116060_bb0175","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s12094-020-02482-9","article-title":"Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies","volume":"23","author":"Sotelo","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.116060_bb0185","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0190","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of Cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.116060_bb0195","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.116060_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103534","article-title":"Immuno-oncology therapy in metastatic bladder cancer: a systematic review and network meta-analysis","volume":"169","author":"Chierigo","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.intimp.2025.116060_bb0205","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.116060_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132398","article-title":"Advancements in first-line treatment of metastatic bladder Cancer: EV-302 and Checkmate-901 insights and future directions","volume":"16","author":"Srinivasalu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.116060_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2025.116060_bb0220","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2021.39.15_suppl.4528","article-title":"Study EV-103: update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"39","author":"Friedlander","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.116060_bb0225","doi-asserted-by":"crossref","unstructured":"L, Z., K W, Y., S, Z., X Q, Y., S M, L., H Y, X., J, L., Y Q, L., B X, T., Z H, C., et al. (2024). Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study. Ann. Oncol. 36. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.002.","DOI":"10.1016\/j.annonc.2024.12.002"},{"key":"10.1016\/j.intimp.2025.116060_bb0230","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA approval summary: Enfortumab Vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","author":"Brave","year":"2024","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.intimp.2025.116060_bb0235","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/JU.0000000000001199","article-title":"Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors","volume":"204","author":"Sonpavde","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.intimp.2025.116060_bb0240","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00280-022-04459-7","article-title":"An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next","volume":"90","author":"D\u2019Angelo","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2025.116060_bb0245","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/geno.2002.6834","article-title":"A new gene family (FAM9) of low-copy repeats in Xp22.3 expressed exclusively in testis: implications for recombinations in this region","volume":"80","author":"Martinez-Garay","year":"2002","journal-title":"Genomics"},{"key":"10.1016\/j.intimp.2025.116060_bb0250","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3892\/or.2013.2592","article-title":"FAM9C plays an anti-apoptotic role through activation of the PI3K\/Akt pathway in human hepatocellular carcinoma","volume":"30","author":"Zhou","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.intimp.2025.116060_bb0255","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2174\/1568026043387908","article-title":"Chemistry-based design of inhibitors for carboxypeptidase a","volume":"4","author":"Kim","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"issue":"1947\u20131955","key":"10.1016\/j.intimp.2025.116060_bb0260","article-title":"Antimicrobial late cornified envelope proteins: the psoriasis risk factor deletion of LCE3B\/C genes affects microbiota composition","volume":"142","author":"Niehues","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2025.116060_bb0265","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/bjd.14284","article-title":"Late cornified envelope (LCE) proteins: distinct expression patterns of LCE2 and LCE3 members suggest nonredundant roles in human epidermis and other epithelia","volume":"174","author":"Niehues","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2025.116060_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083922","article-title":"Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology","volume":"8","author":"Hsin","year":"2013","journal-title":"PloS One"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925020491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925020491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:57:42Z","timestamp":1771520262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925020491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":54,"alternative-id":["S1567576925020491"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116060","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line therapies analysis in advanced\/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116060"}}